• Li-Li Zhou, Zhen-Gang Yuan, Wei-Jun Fu, Hao Xi, Chun-Yang Zhang, Hai-Feng Lan, Xin Zhang, Yu Chen, Wen-Yu Liu, and Jian Hou.
• Division of Hematology, Changzheng Hospital, Second Millitary Medical University, Shanghai 200003, China.
• Chin. Med. J. 2011 Oct 1; 124 (19): 2975-80.

BackgroundAutologous stem cell transplantation (ASCT) is a part of the standard induction therapy of multiple myeloma (MM). This case-controlled clinical trial aimed to further evaluate the therapeutic effects of ASCT as a consolidation therapy for MM and discuss factors influencing the prognosis.MethodsClinical data of 70 patients diagnosed as MM who received ASCT as a consolidation therapy in our hospital between October 1998 and August 2010 were analyzed retrospectively (ASCT group). Other 70 MM patients receiving routine chemotherapy without ASCT (non-ASCT group) during the same period were used as controls. Differences in the degree and duration of remission, progression-free survival (PFS) and overall survival (OS) were compared to explore factors that may influence the prognosis.ResultsThe median follow-up period was 38 months (range 1 - 128 months). The complete response (CR) rate of ASCT group increased from 27.1% (19/70) before ASCT to 51.4% (36/70) after ASCT. The median PFS of ASCT group was significantly higher than non-ASCT group (45 months vs. 25 months, P < 0.001). The median OS of ASCT group was also significantly higher (55 months vs. 30 months, P = 0.016). Single-factor analysis showed that International Staging System (ISS) stage, very good partial response (VGPR) or better outcome were significantly correlated with PFS and OS (P < 0.001). Multi-factor analysis showed that whether or not VGPR or better outcome was achieved were independent factors influencing the disease prognosis.ConclusionUsed as a consolidation therapy, ASCT can achieve better responses and higher OS and PFS of MM patients.

14 keywords...

hide…